A federal appeals court has ruled that the shortage of GLP-1 drugs such as semaglutide is now resolved, allowing the FDA to prevent compounding pharmacies from producing unapproved copies of these medications. The decision, which overturns a lower court order, is a significant victory for drugmakers like Novo Nordisk and Eli Lilly who argued that the shortage had ended. Compounders had been allowed to make cheaper versions during the shortage, but the court sided with the FDA and the drug companies.

Key Takeaways

  • The U.S. Court of Appeals for the Fifth Circuit lifted a temporary injunction that had allowed compounding pharmacies to continue making GLP-1 drugs.
  • The FDA determined that the shortage of drugs like semaglutide and tirzepatide is no longer a public health issue.
  • Compounders argued that the shortage was not truly over, but the court disagreed, citing FDA data and manufacturer supply updates.
  • Patients who relied on compounded versions may now face higher costs or limited access, as only brand-name drugs remain available.
  • The ruling does not affect existing compounding for individual patients with specific medical needs, but bulk production for general use is prohibited.

Background on Compounding During Drug Shortages

Compounding pharmacies are allowed to make customized versions of FDA-approved drugs when a shortage is declared. During the COVID-19 pandemic and subsequent years, demand for GLP-1 receptor agonists for weight loss and diabetes skyrocketed, leading to persistent shortages of brand-name drugs like Ozempic, Wegovy, and Mounjaro. The FDA placed these drugs on its shortage list, which permitted compounding pharmacies to produce and sell unapproved copies.

These compounded versions were often much cheaper and more accessible for patients who could not find or afford the brand-name drugs. However, the FDA and drugmakers argued that the shortage had ended by late 2023, as manufacturing capacity increased. The agency removed the drugs from the shortage list, but a group of compounding pharmacies sued to keep producing them.

The Legal Dispute and Court Ruling

In a closely watched case, the Outsourcing Facilities Association, representing compounding pharmacies, challenged the FDA’s decision to remove semaglutide and tirzepatide from the shortage list. A Texas federal judge initially sided with the compounders, issuing a preliminary injunction that allowed them to continue production. That injunction was based on the argument that the FDA had not properly evaluated whether the shortage was truly over.

On appeal, the Fifth Circuit reversed that decision. The appeals court found that the FDA had followed proper procedures and that the evidence showed adequate supply from manufacturers. The ruling means that compounding pharmacies can no longer mass-produce these drugs. The decision is a blow to the compounding industry, which had grown rapidly during the shortage.

Impact on Patients and Access to GLP-1 Drugs

For patients who relied on compounded GLP-1 drugs, the ruling may mean higher out-of-pocket costs. Brand-name drugs are expensive, often costing over $1,000 per month without insurance, and many insurance plans do not cover them for weight loss. Compounded versions were typically much cheaper. Some patients may also face difficulty finding a doctor willing to prescribe the brand-name drugs, as insurance coverage remains inconsistent.

However, the ruling does not completely eliminate access to compounding. The FDA still allows compounding for individual patients with a valid prescription and a documented medical need, such as an allergy to an ingredient in the brand-name drug. But bulk production for general inventory is no longer permitted. This change could strain community pharmacies that served many patients through the shortage.

Future of Compounded GLP-1 Medications

The court’s decision sets a precedent for how the FDA handles drug shortages and compounding. Going forward, compounding pharmacies will have to rely on the agency’s shortage list to justify bulk production. If the FDA determines a shortage is over, they must stop. Drugmakers are expected to continue monitoring supply and may push for stricter enforcement to protect their market share.

Some health policy experts note that the compounding industry may shift its focus to other drugs that remain in shortage. However, the high demand for GLP-1 drugs means that patients will likely continue to seek alternatives. The FDA has also warned about safety risks with compounded drugs, including contamination and incorrect dosing, which played a role in the agency’s argument for ending the exception.

Frequently Asked Questions

What does the court ruling mean for patients currently using compounded GLP-1 drugs?

Patients who are already using compounded GLP-1 drugs may still be able to obtain them through a pharmacy that prepares individual prescriptions for specific medical needs. But mass-produced compounded versions from outsourcing facilities are no longer allowed. Patients should talk to their doctor about switching to a brand-name drug or finding a compounding pharmacy that can make a personalized version.

Why did the court side with the FDA and drugmakers?

The appeals court found that the FDA had properly determined the shortage was over based on manufacturer reports and supply data. The court also said that allowing compounding to continue indefinitely would undermine the incentives for drugmakers to develop and maintain a stable supply. The ruling affirms the FDA’s authority to manage shortage lists and limit compounding to those periods when brand-name drugs are genuinely unavailable.

Are compounded GLP-1 drugs safe?

The FDA has raised concerns about the safety of compounded drugs because they are not subject to the same quality controls as brand-name products. There have been reports of contamination, incorrect dosages, and adverse events. The agency recommends that patients use FDA-approved drugs whenever possible and only consider compounded versions under a doctor’s supervision when a shortage exists and no alternative is available.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.